Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
Lobo
Evelyn D
ED
Lilly Research Laboratories, Indianapolis, Indiana 46285-0724, USA. loboev@lilly.com
Robertson-Plouch
Carol
C
Quinlan
Tonya
T
Hong
Quan
Q
Bergstrom
Richard F
RF
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D015337:Multicenter Studies as Topic; D000077152:Olanzapine; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*; D012727:Sex Characteristics
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine